Spyre Therapeutics (SYRE) Stock Forecast: StockMap's 2-Week Call
SYRE stock forecast: StockMap's model makes no two-week call on Spyre Therapeutics after the Nov 19 close: its evidence is split, 8 reasons for and 7 against. Too few two-week windows graded to judge yet.
Spyre Therapeutics last closed at $97.63, -3.77% on the session.
Against the IVW growth benchmark the position is -1.44% over the forecast window.
Spyre Therapeutics' market cap is $9.27B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 13 (too close to call).
Where SYRE sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 8 bullish and 7 bearish.
Agreement across those insights is 53%.
2 daily calls for SYRE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Spyre Therapeutics in the 21st percentile on return on equity, where 100 is best.
Spyre Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Spyre Therapeutics as the 28th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Spyre Therapeutics ranks 33rd of 394 in the group, against a group median of -0.27.